Gileaddi Paveso Phosphorous Bwe (trade name Harvoni) is about to be approved for listing in China

recently, Gileaddi Paeveso phosphorous buwe tablets (trade name Harvoni) in China's import listing application entered the "in the approval" stage, this hepatitis C drug will soon be approved in the domestic market, for the benefit of domestic hepatitis patientsHarvoni
Harvoni is a daily compound single-chip cocktail therapy developed by Gilead, a compound formulation consisting of the nucleotide-like polymerase inhibitor Sofosbuvir and the fixed-dose protease NS5A inhibitor LedipasvirOctober 2014, Harvoni was approved by theFDA(approved for treatment in adult patients with genotype 1 C) and is the world's first approved daily all-oral interferon-free hepatitis C cocktail therapy for the treatment of genotype 1 hepatitis C infection, which Harvoni can use in combination with other oral preparations such as ribavirin, which will become the gold standard for clinical treatment of hepatitis COctober 2017, Gilead announced that The Study Paeve 90mg/Sofobuvir 400mg (LDV/SOF) for the treatment of the gene-like hepatitis 1 Chinese hepatitis C
patients with or without compensatory cirrhosis(results: 206 patients in the 18 research structures from China received 100% continuous viral response after 12 weeks of LDV/SOF treatment)This result is also the basis for Harvoni's domestic approvalIn September 2017, Jidai Sovaldi was approved in China for the use of otherdrugs(treatment of adult semen and 12 to 18-year-olds with genotype 2 and 3 hepatitis C), which is Gilead's first hepatitis C drug approved in ChinaMay 2018, The Ji-San Epclusa was approved for use in adult patients with gene 1-6, hybrid and unknown chronic HCV infectionsWith the imminent approval of the second generation of Harvoni, the Chinese market has become a driving force for Gilead's future growth